Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Terveystalo Plc: Managers’ Transactions (Hasselberg)

Terveystalo Plc, Managers’ transactions, 2 November 2023 at 16:00 EET On 23 March 2023, Terveystalo Plc’s Annual General Meeting resolved that the annual remuneration of the Board will be paid as a combination of Company's shares and cash in such a manner that 40% of the annual remuneration is paid in the Company's shares, which will be purchased from the market on behalf of the members of the Board of Directors at a price determined in public trading, and 60% is paid in cash. Annual General Meeting also resolved that the shares will be purchased within a period of two weeks beginning

Terveystalo Plc: Managers’ Transactions (Kauniskangas)

Terveystalo Plc, Managers’ transactions, 2 November 2023 at 16:00 EET On 23 March 2023, Terveystalo Plc’s Annual General Meeting resolved that the annual remuneration of the Board will be paid as a combination of Company's shares and cash in such a manner that 40% of the annual remuneration is paid in the Company's shares, which will be purchased from the market on behalf of the members of the Board of Directors at a price determined in public trading, and 60% is paid in cash. Annual General Meeting also resolved that the shares will be purchased within a period of two weeks beginning

Terveystalo Plc: Managers’ Transactions (Lehtoranta)

Terveystalo Plc, Managers’ transactions, 2 November 2023 at 16:00 EET On 23 March 2023, Terveystalo Plc’s Annual General Meeting resolved that the annual remuneration of the Board will be paid as a combination of Company's shares and cash in such a manner that 40% of the annual remuneration is paid in the Company's shares, which will be purchased from the market on behalf of the members of the Board of Directors at a price determined in public trading, and 60% is paid in cash. Annual General Meeting also resolved that the shares will be purchased within a period of two weeks beginning

New from NOMOS: The icon in a luxury limited edition

The limited anniversary editions that NOMOS Glashütte produces in honor of Glashütte's watchmaking tradition are legendary—and usually sell out quickly. This fall, the watchmaking company is continuing the series with the timepiece that has been considered an icon for decades: 175 Tangente are now available in 18 kt rose gold.GLASHÜTTE, NOVEMBER 2, 2023. How best to describe Tangente rose gold neomatik - 175 Years Watchmaking Glashütte? The words dapper and sophisticated immediately come to mind—as well as chic, elegant, and stylish. With this new limited edition in rose gold, NOMOS

Swedish Export Credit Corporation (SEK) has priced new AUD 500m 7-year Benchmark

PRESS RELEASE – 2 November 2023   On Tuesday 24th October 2023, SEK, rated Aa1 / AA+ (stable / stable) by Moody’s and S&P, successfully priced a new 7-year AUD 500m Kangaroo benchmark, its second AUD 500m Kangaroo benchmark this year. The transaction, due 1st November 2030 pays a semi-annual coupon of 5.40% and was priced at a spread of SQ ASW+75bps (ACGB+91.5bps) with a reoffer yield of 5.43%. Joint Lead Managers on the transaction were Nomura, RBC Capital Markets, and TD Securities.    •       SEK issued an initial marketing announcement at 10:04am Sydney time on Friday the

Tailored to the perfect size: the new Ahoi neomatik 38 date

Compact timekeeping: the new Ahoi neomatik 38 date from NOMOS Glashütte is powered by the automatic caliber DUW 6101, which was previously only used in cases over 40 mm in diameter.GLASHÜTTE, OCTOBER 25, 2023. The NOMOS caliber DUW 6101 is something special: a slim, very efficient automatic movement developed and manufactured in-house. Until now, it was only found in watch cases with a diameter of more than 40 millimeters, but now it also fits into a smaller NOMOS watch: the new Ahoi neomatik 38 date. How? For the new ideal dimensions, the date ring of the slim movement was adjusted,

Preliminary result of Crayfish BidCo Oy’s voluntary recommended public cash tender offer for all shares in Caverion Corporation

Caverion Corporation Tender Offer 2 November 2023 at 15.10 p.m. (EET)Preliminary result of Crayfish BidCo Oy’s voluntary recommended public cash tender offer for all shares in Caverion Corporation NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. FOR FURTHER INFORMATION, PLEASE SEE SECTION ENTITLED “IMPORTANT INFORMATION” BELOW. Crayfish BidCo Oy has today published the following

Air Canada to establish at Stockholm Arlanda Airport – will launch two direct routes to Montreal and Toronto

Canada's largest airline, Air Canada, will establish at Stockholm Arlanda Airport with two direct routes, one of which is a new destination – Montreal – on June 12[th] as of next year. Operating direct routes to Toronto and Montreal five times a week, Air Canada will be an important addition to Stockholm Arlanda, connecting the Swedish capital with Canada as well as the North American market. Air Canada, as a founding member of Star Alliance and as the largest provider of scheduled passenger services on the domestic and international market to and from Canada, will establish at Stockholm

Elisa sells majority stake in Elisa Videra's business

ELISA INVESTOR NEWS RELEASE, 2 NOVEMBER 2023 AT 3:05 PMThe businesses of Elisa Corporation's subsidiary Elisa Videra and the German company MVC Mobile VideoCommunication GmbH (owned by KLP Vermögensverwaltungs GmbH) will be combined into MVC. KLP will have a 62.5% holding and Elisa 37.5% of MVC Videra. The transaction is being conducted as a share swap. Going forward, the company will not be consolidated into the Elisa Group. The transaction is subject to approval by authority in Finland, and the estimated closing is in December 2023. In line with its international businesses strategy,

BerGenBio Announces Poster Presentation at Upcoming ASH Meeting

BERGEN, Norway, November 2, 2023, BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster highlighting final results from a clinical study of its highly selective AXL inhibitor bemcentinib in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) will be presented during the American Society of Hematology (ASH) Annual Meeting being held December 9-12, 2023 in San Diego, CA.   Poster Details: Publication Number: 4287Title: Phase Ib/II

Dr. Kevin J. Tracey receives Hans Wigzell Research Foundation’s Science Prize amounting to USD 100.000

The Hans Wigzell Research Foundation (Hans Wigzells Forskningsstiftelse) awards its annual scientific prize to Kevin J. Tracey, MD, president and CEO, at the Feinstein Institutes for Medical Research. Dr. Tracey receives the prize of USD 100.000 for his contributions to the fields of neuroscience and neuroimmunology and his pioneering discoveries in vagus nerve stimulation, the inflammatory reflex and bioelectronic medicine.   Dr. Tracey’s discovery of the body’s “inflammatory reflex” – a neural circuit regulating inflammatory responses, is on of his most important achievements. This

Faron to present data from BEXMAB study at ASH

Faron to present Phase 1/2 data from BEXMAB Study of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies at the 65th American Society of Hematology Annual Meeting   TURKU, Finland / BOSTON, Massachusetts - November 2, 2023 - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that it will present Phase 1/2 data from its ongoing BEXMAB study of bexmarilimab in combination with standard of care (SoC) in relapsed/refractory (r/r) acute myeloid

Inna Braverman Receives the Prestigious Global Leadership Award from Vital Voices by Former Secretary of State Hillary Clinton

Secretary Clinton praised Braverman and the five honorees for “defying the status quo” and “harnessing the power of waves.” Former Secretary of State Hillary Clinton, andInna Braverman, Founder and CEO of Eco WavePower Washington, U.S. (November 2, 2023) – Eco Wave Power Global AB (publ) (Nasdaq Capital Market: WAVE) (“Eco Wave Power” or the “Company”), a leading, publicly traded onshore wave energy company, is pleased to announce that Inna Braverman, the company’s Founder and Chief Executive Officer, received the Vital Voices’ Global Leadership Award. Vital Voices which

Medius Appoints Craig Keller as US Vice President of Payment Strategy

Medius , a leading provider of AP Automation and wider Spend Management Solutions, today announces the appointment of Craig Keller  as Vice President of Payment Strategy.As Medius’ Vice President of Payment Strategy, Keller will drive the organization’s optimized digital payments strategy, as well as building strategic value within the buyer-supplier trading partnership by optimizing payment processes and ensuring seamless and efficient financial transactions.  Keller’s appointment is the latest development in a momentous

Quickbit starts collaboration with e-commerce platform Abicart - gives access to approximately 2500 merchants

Today, Quickbit announces that a cooperation agreement has been signed with the Swedish e-commerce platform Abicart. It gives Quickbit access to approximately 2,500 e-commerce companies, which are given the opportunity to activate Quickbit Pay to their website without further integration.Abicart is a Swedish e-commerce platform that allows e-commerce companies to in to set up their own websites for the sale of goods and services in a simple way and in subscription form. By targeting small and medium-sized e-commerce companies, Abicart has built up a customer base of approximately 2,500 e-

Nokian Tyres reached one of its key climate targets seven years ahead of schedule – The level of the company’s direct CO2 emissions is the lowest in the tire industry

Nokian Tyres plc Press Release November 2, 2023 at 2.50 p.m. EET Nokian Tyres has reached one of its key emissions reduction targets seven years ahead of schedule. One of the company’s science-based greenhouse gas emissions reduction targets was to cut its tire factories’ CO2 emissions by 52% per production ton by 2030 compared to the emissions level in 2015. The target was already achieved in 2023. Nokian Tyres’ factory emissions per production ton are the lowest in the tire industry, but the company continues its work to reduce them even more. In 2015 the direct CO2 emissions from

Raisio plc: Managers´ transactions

Raisio plc Managers´ transactions 2 November 2023   MANAGERS’ TRANSACTIONS   Person subject to the notification requirement Name: Mika Saarinen Position: Chief Financial Officer Issuer: Raisio Oyj LEI: 74370083282NHIP4QD02   Notification type: INITIAL NOTIFICATION Reference number: 42338/5/4 ____________________________________________   Transaction date: 2023-11-02 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009002943 Nature of transaction: ACQUISITION   Transaction details (1): Volume: 19 Unit price: 2.06

Sivers Semiconductors invites to Capital Markets Day 2023

Sivers Semiconductors AB (publ) invites institutional investors, financial analysts and the media to a capital markets day in Stockholm on November 21, 2023.The purpose of the day is to increase the understanding of Sivers Semiconductor's operations, how the company, through its innovative, competitive products, meets the need for upgraded technology and infrastructure for several megatrends and strengthens its position in fast-growing markets such as optical communication and satellite communication. Presentations will be held by group management as well as customers and partners.

Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock Inc.’s holding in Metso

Metso Corporation’s stock exchange release on November 2, 2023, at 2:00 p.m. EETMetso Corporation has received a notification, pursuant to Chapter 9, Section 5 and 6 of the Finnish Securities Markets Act, about a change in the shareholding of BlackRock, Inc. On November 1, 2023, BlackRock's holding in Metso’s shares amounted to 40,855,008 shares or 4.92 percent of total shares and votes. BlackRock's holding through financial instruments in Metso amounted to 818,121 shares, which corresponds to 0.09 percent of the total amount of Metso’s shares. As a result, BlackRock's total position

Form 8.3 - Dechra Pharmaceuticals PLC

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.         KEY INFORMATION (a) Full name of discloser: Magnetar Capital Partners LP(b) Owner or controller of interests and shortpositions disclosed, if different from 1(a):    The naming of nominee or vehicle companies isinsufficient.  For a trust, the trustee(s),settlor and beneficiaries must be named.(c) Name of offeror/offeree in relation to whose Dechra

Akobo Minerals AB (publ): New share capital registered

Oslo, 02 November 2023, Akobo Minerals AB  (Euronext and Frankfurt: AKOBO) (OTCQX:AKOBF).   Reference is made to the stock exchange announcement published by Akobo Minerals AB ("Akobo" or the "Company") on 01 November 2023 regarding exercise of warrants. Today, the new share capital was registered with the Swedish Companies Registration Office (Sw: "Bolagsverket").   Following registration, the Company has a share capital of SEK 1,975,058.687229 divided

Newsletter from Hamlet Biopharma

Hamlet Biopharma  An innovative pharmaceutical company with a wide and robust portfolio ofprojects for the treatment of cancer and infections. Cancer A central goal of cancer therapy is to selectively target the tumor andminimize toxicity for healthy tissue. Hamlet Biopharma is developing newtherapeutic solutions for targeting and killing tumor cells with greaterprecision. Alpha1H is one of Hamlet Biopharma’s main drug candidates. Alpha1His a synthetically manufactured peptide in complex with oleic acid and anefficient anti-tumor drug candidate for the

There are no items matching the current filter
There are no more items matching the current filter
Back to top